Credit Suisse analyst Kennen MacKay commented on reports that Medivation has hired bankers to defend from an acquisition. The analyst said Medivation has become vulnerable to a takeover following the pullback in share, though conversations with management suggest they are not interested in selling. MacKay's analysis suggests Medivation could be worth $54-$59/sh on operational synergies, and $60-$75/sh with leveraged tax benefits to potential suitors Sanofi, AstraZeneca, and Roche, who have expressed interest in acquiring US oncology companies. The analyst raised his price target on Medivation to $49 from $48 and reiterated his Outperform rating.